Trial reportJSLS : Journal of the Society of Laparoendoscopic Surgeons
Reliability of Likert Scale for Surgeon-Rated Conspicuity of Ureters with Pudexacianinium Chloride (ASP5354).
Trial report in JSLS : Journal of the Society of Laparoendoscopic Surgeons. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04238481 (A Phase 2 Randomized Open-label, Dose-ranging Study for Ureter Visualization Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Randomized Open-label, Dose-ranging Study for Ureter Visualization Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pudexacianinium chloride is a novel near-infrared fluorescence (NIR-F) imaging agent under evaluation for ureter visualization in patients undergoing abdominopelvic surgery. Methods: Surgeons were trained to use the Likert scale. Each surgeon rated 36 color image pairs (white light and NIR-F on the same anatomical area) from the phase 2 trial (NCT04238481), in which adults undergoing abdominopelvic surgery received single doses of pudexacianinium. Surgeons rated a single-item question, "How conspicuous is the ureter?" using a 5-point Likert scale ranging from 1 = none (not self-evident) to 5 = excellent (extremely self-evident). Images were taken at the beginning (10-30 minutes postpudexacianinium, n = 18 pairs), middle (between 30 minutes postpudexacianinium and end of surgery, n = 13 pairs), and end of surgery (n = 5 pairs) and were displayed for 30 seconds. Inter-rater reliability at baseline and intra-rater reliability after 1 week from baseline were evaluated using intraclass correlation coefficients (ICCs) with target values set a priori as 0.70 and 0.80 for inter-rater and intra-rater reliability, respectively. Results: Seventeen surgeons were enrolled and completed baseline ratings; 15 completed retest ratings. Mean (standard deviation) rating on the 5-point Likert scale with NIR-F was 3.77 (0.98) at baseline and 3.84 (0.97) at retest and 2.28 (0.98) at baseline and 2.16 (0.95) at retest with white light. Inter-rater reliability ICC was 0.70 (95% confidence interval [CI] = 0.63, 0.78) and intra-rater reliability ICC was 0.82 (95% CI = 0.80, 0.84). Conclusions: The 5-point Likert scale had adequate inter- and intra-rater reliability among surgeons for assessing ureter conspicuity in patients who received pudexacianinium during abdominopelvic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.